Breaking News

Algorithme Pharma, HMR in Patient Access Pact

By Kristin Brooks | December 11, 2013

To offer patient access in key therapeutic areas

Algorithme Pharma has partnered with Hôpital Maisonneuve-Rosemont (HMR) to offer sponsors increased patient access in key therapeutic areas, including hematology, oncology, nephrology, ophthalmology and metabolic diseases. The HMR clinical research team has more than 60 clinicians and is supported by approximately 75 employees. 
“As sponsors look to obtain more information on their lead drug earlier in development, the need to include patient populations in early stage clinical trials continues to increase. Partnering with research teams who have expertise in key therapeutic areas advances our goal of providing a full spectrum of Phase I/IIa clinical research services to our diverse client base,” said Dr. Marc Lefebvre, vice president Scientific & Regulatory Affairs, Algorithme Pharma.
Dr. Pierre Dubé, associate director, Clinical Research Division, Hôpital Maisonneuve-Rosemont, added, “In this partnership between private and academic organizations, our clinical investigators and researchers will be able to leverage Algorithme Pharma’s immense wealth of knowledge. For HMR and its Research Centre, this kind of collaboration is part of our strategic objectives which aim to continually deliver innovative treatments to our patients.”

Related Compliance:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research